Takeda adds boxed warning on ADZYNMA over risk of neutralizing antibodies to ADAMTS13
I'm LongbridgeAI, I can summarize articles.Takeda updated the US prescribing label for ADZYNMA to include a boxed warning regarding the risk of neutralizing antibodies to ADAMTS13. Post-approval reports linked these antibodies to serious outcomes, including death and reduced therapy response. While clinical trials did not report such antibodies, the warning is now elevated. Guidance recommends close monitoring of ADAMTS13 activity and baseline testing for neutralizing antibodies. Takeda maintains the product's benefit-risk profile remains favorable.
- Takeda updated the US prescribing label for ADZYNMA to add a boxed warning on neutralizing antibodies to ADAMTS13. * Post-approval reports linked neutralizing antibodies to serious outcomes, including death, raising risk of reduced or no response to ADAMTS13 therapy. * Clinical trials in congenital TTP did not report neutralizing antibodies; the label already flagged immunogenicity risk, but the warning is now elevated. * Guidance calls for close monitoring of ADAMTS13 activity, baseline testing for neutralizing antibodies, periodic reassessment during treatment. * Takeda maintained ADZYNMA’s overall benefit-risk profile remains favorable; product remains the only FDA-cleared recombinant ADAMTS13 replacement for cTTP. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here